1. Design, synthesis and analysis of novel sphingosine kinase-1 inhibitors to improve oral bioavailability
- Author
-
Jason C. Hurlbert, Morgan T. Turnow, Mikala R. Smith, William E. Cotham, Angel A. Castro, Caylie A. McGlade, Kevin M. Mays, Louise M. Hardwick, Tiffany S. Dwyer, Kendarius J. Butler, Sara G. Manore, Lisa N. Hair, Michael D. Walla, Melody C. Iacino, T. Christian Grattan, Matthew R. Wilson, Stephanie R. Woodson, and Erin W. Parker
- Subjects
Models, Molecular ,Ceramide ,Protein Conformation ,Clinical Biochemistry ,Sphingosine kinase ,Pharmaceutical Science ,Biochemistry ,Article ,chemistry.chemical_compound ,Inhibitory Concentration 50 ,Structure-Activity Relationship ,In vivo ,Drug Discovery ,Humans ,Enzyme Inhibitors ,Molecular Biology ,Adaptor Proteins, Signal Transducing ,biology ,Sphingosine ,Molecular Structure ,Chemistry ,Organic Chemistry ,In vitro ,Molecular Docking Simulation ,Sphingosine kinase 1 ,Drug Design ,biology.protein ,Molecular Medicine ,Sphingomyelin ,Intracellular - Abstract
The sphingomyelin pathway is important in cell regulation and determining cellular fate. Inhibition of sphingosine kinase isoform 1 (SK1) within this pathway, leads to a buildup of sphingosine and ceramide, two molecules directly linked to cell apoptosis, while decreasing the intracellular concentration of sphingosine-1-phosphate (S1P), a molecule linked to cellular proliferation. Recently, an inhibitor capable of inhibiting SK1 in vitro was identified, but also shown to be ineffective in vivo. A set of compounds designed to assess the impact of synthetic modifications to the hydroxynaphthalene ring region of the template inhibitor with SK1 to obtain a compound with increased efficacy in vivo. Of these fifteen compounds, 4A was shown to have an IC50 = 6.55 μM with improved solubility and in vivo potential.
- Published
- 2021